HighVista Strategies LLC
Long book
$362.2M
Q1 2026
Positions
156
Top-10 weight
27%
concentration
Last quarter
+22.1%
SPY +14.8%
Turnover
33%
of book per quarter
Strategy in plain words
auto-generated from filingsHighVista Strategies LLC is an institutional manager, specialised in healthcare (64% of the long book), running a $362.2M US long book across 156 positions.
The portfolio is moderately concentrated (top 10 ≈ 27% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: INVESCO DB COMMODITY INDEX T, ABIVAX SA-ADR, PRAXIS PRECISION MEDICINES I, COGENT BIOSCIENCES INC, SPYRE THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 4.2pp per quarter ahead of the S&P 500, beating the index in 6 of 9 quarters. Signal value of individual moves is limited — treat changes as weak evidence.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-3.7%
Q2 2024
+8.5%
Q3 2024
-4.5%
Q4 2024
-9.1%
Q1 2025
+12.5%
Q2 2025
+20.0%
Q3 2025
+30.9%
Q4 2025
+1.1%
Q1 2026
+22.1%
Sector allocation
Healthcare 67%
Technology 11%
Industrials 6%
Other 4%
Utilities 3%
Materials 2%
Consumer discretionary 2%
Services media 2%
Long book by quarter
What does HighVista Strategies own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 26.3K | $8.5M | 2.3% | +1.9% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 197.1K | $7.6M | 2.1% | -41.5% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 146.3K | $7.4M | 2.0% | -22.3% |
| PCVX VAXCYTE INC | Healthcare | 124.6K | $7.2M | 2.0% | +9.3% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 69.3K | $6.7M | 1.9% | -42.4% |
| 430 TERNS PHARMACEUTICALS INC | — | 114.3K | $6.0M | 1.7% | -34.9% |
| NUVL NUVALENT INC-A | Healthcare | 56.6K | $5.8M | 1.6% | -22.8% |
| IMVT IMMUNOVANT INC | Healthcare | 225.1K | $5.6M | 1.5% | +1.5% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 165.2K | $5.5M | 1.5% | +22.3% |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 131.3K | $5.0M | 1.4% | +274.2% |
| AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 352.1K | $4.9M | 1.4% | +47.4% |
| AMZN AMAZON.COM INC | Consumer discretionary | 22.4K | $4.7M | 1.3% | +28.7% |
| LBRX LB PHARMACEUTICALS INC | Healthcare | 173.6K | $4.3M | 1.2% | +23.9% |
| RLAY RELAY THERAPEUTICS INC | Healthcare | 421.9K | $4.2M | 1.2% | -22.6% |
| INSM INSMED INC | Healthcare | 24.3K | $4.0M | 1.1% | -38.3% |
| NVDA NVIDIA CORP | Technology | 22.4K | $3.9M | 1.1% | +57.7% |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 78.9K | $3.9M | 1.1% | New |
| CYTK CYTOKINETICS INC | Healthcare | 58.6K | $3.9M | 1.1% | -48.8% |
| LQDA LIQUIDIA CORP | Healthcare | 99.7K | $3.8M | 1.0% | -36.1% |
| OCUL OCULAR THERAPEUTIX INC | Healthcare | 441.6K | $3.7M | 1.0% | +28.3% |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 52.5K | $3.7M | 1.0% | -2.1% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 49.6K | $3.7M | 1.0% | -38.2% |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 194.0K | $3.6M | 1.0% | New |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 33.9K | $3.6M | 1.0% | -54.0% |
| PALI PALISADE BIO INC | Healthcare | 2.0M | $3.5M | 1.0% | +55.3% |
| DFTX DEFINIUM THERAPEUTICS INC | Materials | 185.9K | $3.5M | 1.0% | New |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 226.5K | $3.5M | 1.0% | New |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 20.4K | $3.5M | 1.0% | +83.6% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 182.9K | $3.3M | 0.9% | +206.7% |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 35.8K | $3.0M | 0.8% | -59.9% |
| GHRS GH RESEARCH PLC | Healthcare | 213.2K | $3.0M | 0.8% | -11.4% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 35.6K | $3.0M | 0.8% | -26.6% |
| MAZE MAZE THERAPEUTICS INC | Healthcare | 99.8K | $3.0M | 0.8% | -41.4% |
| ERAS ERASCA INC | Healthcare | 181.1K | $2.9M | 0.8% | New |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 91.9K | $2.9M | 0.8% | -46.3% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 73.1K | $2.9M | 0.8% | -11.4% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 49.0K | $2.9M | 0.8% | New |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 89.4K | $2.8M | 0.8% | +72.6% |
| VERA VERA THERAPEUTICS INC | Healthcare | 69.2K | $2.8M | 0.8% | New |
| PHVS PHARVARIS NV | Healthcare | 97.9K | $2.8M | 0.8% | -39.7% |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 134.2K | $2.6M | 0.7% | -64.0% |
| ALKS ALKERMES PLC | Healthcare | 73.2K | $2.6M | 0.7% | +177.2% |
| ALMS ALUMIS INC | Healthcare | 112.9K | $2.5M | 0.7% | New |
| MSFT MICROSOFT CORP | Technology | 6.5K | $2.4M | 0.7% | -1.2% |
| EYPT EYEPOINT INC | Healthcare | 183.0K | $2.4M | 0.7% | New |
| LITE LUMENTUM HOLDINGS INC | Technology | 3.1K | $2.2M | 0.6% | -27.8% |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 104.2K | $2.2M | 0.6% | New |
| V VISA INC-CLASS A SHARES | Services media | 7.1K | $2.2M | 0.6% | +13.5% |
| GH GUARDANT HEALTH INC | Healthcare | 23.4K | $2.2M | 0.6% | -36.5% |
| HPE HEWLETT PACKARD ENTERPRISE | Technology | 90.0K | $2.1M | 0.6% | +18.1% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 156 | $362.2M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 145 | $388.3M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 148 | $408.0M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 146 | $272.1M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 148 | $259.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 137 | $268.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 142 | $290.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 138 | $273.8M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 131 | $280.4M | canonical | SEC ↗ |